MIST Milestone Pharmaceuticals Inc. Stock Quote

MIST [NASD]

Index	-	P/E	-	EPS (ttm)	-1.05	Insider Own	9.28%	Shs Outstand	42.24M	Perf Week	-9.09%
Market Cap	153.52M	Forward P/E	-	EPS next Y	-1.63	Insider Trans	0.00%	Shs Float	27.15M	Perf Month	-26.13%
Income	-44.30M	PEG	-	EPS next Q	-0.37	Inst Own	75.20%	Short Float	6.89%	Perf Quarter	-13.46%
Sales	15.00M	P/S	10.23	EPS this Y	39.80%	Inst Trans	0.05%	Short Ratio	17.25	Perf Half Y	-3.57%
Book/sh	2.39	P/B	2.26	EPS next Y	-54.70%	ROA	-35.10%	Target Price	14.40	Perf Year	-2.70%
Cash/sh	3.52	P/C	1.53	EPS next 5Y	-	ROE	-36.90%	52W Range	3.98 - 8.24	Perf YTD	-17.56%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-38.30%	52W High	-34.34%	Beta	-
Dividend %	-	Quick Ratio	22.80	Sales past 5Y	-	Gross Margin	-	52W Low	35.93%	ATR	0.52
Employees	29	Current Ratio	22.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.21	Volatility	8.70% 8.19%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-9.30%	Profit Margin	-	Rel Volume	0.08	Prev Close	5.40
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 BMO	Payout	-	Avg Volume	108.44K	Price	5.41
Recom	1.80	SMA20	-15.27%	SMA50	-12.32%	SMA200	-11.28%	Volume	1,070	Change	0.19%

Apr-22-22

Upgrade

Piper Sandler

Neutral → Overweight

$8 → $10

Mar-05-21

Initiated

H.C. Wainwright

Buy

$20

Jul-29-20

Upgrade

Oppenheimer

Perform → Outperform

$18

Jul-24-20

Upgrade

Jefferies

Hold → Buy

Mar-25-20

Downgrade

Jefferies

Buy → Hold

$28 → $3

Mar-24-20

Downgrade

Piper Sandler

Overweight → Neutral

$26.50 → $3

Mar-24-20

Downgrade

Oppenheimer

Outperform → Perform

Jun-04-19

Initiated

Oppenheimer

Outperform

$32

Jun-03-19

Initiated

Piper Jaffray

Overweight

$26.50

Jun-03-19

Initiated

Jefferies

Buy

$28

Jun-03-19

Initiated

Cowen

Outperform

$32

May-12-22 07:15AM	Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update CNW Group -7.40%
Apr-30-22 09:00AM	Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT PR Newswire
09:00AM	Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT CNW Group
Apr-15-22 04:41PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
04:41PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
10:20AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have made a respectable return of 36% over the past year Simply Wall St.
Apr-14-22 07:00AM	Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT PR Newswire
07:00AM	Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT CNW Group
Mar-24-22 07:20AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update CNW Group +9.28%
Mar-01-22 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences CNW Group
Feb-16-22 07:00AM	Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer PR Newswire -5.41%
07:00AM	Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer CNW Group
Feb-14-22 01:03PM	Could The Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jan-04-22 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference PR Newswire
07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference CNW Group
Dec-14-21 07:56AM	Milestone Pharmaceuticals (NASDAQ:MIST) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Nov-15-21 07:00AM	Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT PR Newswire +13.93%
Nov-12-21 07:20AM	Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update PR Newswire +8.93%
07:20AM	Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update CNW Group
Nov-11-21 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences CNW Group
Oct-15-21 09:31AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 18% over the last year Simply Wall St.
Sep-22-21 07:00AM	Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference PR Newswire
07:00AM	Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference CNW Group
Sep-07-21 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire -5.99%
07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference CNW Group
Aug-16-21 10:58AM	What Kind Of Shareholders Own Milestone Pharmaceuticals Inc. (NASDAQ:MIST)? Simply Wall St.
Aug-11-21 04:18PM	Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update PR Newswire
04:18PM	Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update CNW Group
Aug-03-21 09:01AM	10 Stocks to Buy According to Neil Shahrestanis Ikarian Capital Insider Monkey -6.56%
May-26-21 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference PR Newswire
07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference CNW Group
May-17-21 01:22PM	Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China Benzinga
07:02AM	Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21 PR Newswire
07:02AM	Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21 CNW Group
07:01AM	Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update PR Newswire
07:01AM	Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update CNW Group
07:00AM	Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China PR Newswire
07:00AM	Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China CNW Group
May-04-21 09:04AM	Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day Zacks -5.27%
May-03-21 06:47AM	We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely Simply Wall St.
Apr-02-21 11:59AM	Milestone Pharmaceuticals Stock Is a Bet On Etripamil InvestorPlace
Mar-29-21 05:32PM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update PR Newswire
05:32PM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update CNW Group
05:30PM	Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate PR Newswire
05:30PM	Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate CNW Group
Mar-05-21 10:29AM	Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021 Benzinga +5.98%
Feb-25-21 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences CNW Group
Feb-01-21 04:35AM	How Much Of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Do Institutions Own? Simply Wall St.
Jan-29-21 05:13PM	Liberty Health Sciences Reports Fiscal Year 2021 Third Quarter Financial Results CNW Group
Dec-02-20 10:11PM	Is Milestone Pharmaceuticals (MIST) A Good Stock To Buy Now? Insider Monkey
06:08AM	TAICCA and Golden Horse FPP Series Introduce Promising Proposals to International Investors CNW Group
Nov-23-20 04:44PM	Government of Canada Creates Task Force on Flood Insurance and Relocation CNW Group
07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences CNW Group
Nov-18-20 07:00AM	Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT PR Newswire
07:00AM	Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT CNW Group
Nov-13-20 07:00AM	Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update PR Newswire
07:00AM	Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update CNW Group
Nov-11-20 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference PR Newswire
Oct-23-20 07:00AM	Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants PR Newswire -14.29%
07:00AM	Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants CNW Group
Oct-22-20 04:01PM	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants PR Newswire
04:01PM	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants CNW Group
Sep-22-20 07:00AM	Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments PR Newswire
Sep-08-20 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences CNW Group
Aug-12-20 07:00AM	Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update PR Newswire
Aug-10-20 07:47AM	Why Earnings Season Could Be Great for Milestone Pharmaceuticals (MIST) Zacks
Aug-06-20 07:00AM	Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference PR Newswire
Aug-04-20 09:04AM	How Many Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Do Institutions Own? Simply Wall St.
Jul-31-20 12:34PM	Oppenheimer: These 3 Strong Buy Stocks Have Over 50% Upside Potential TipRanks
Jul-24-20 06:17PM	Milestone Pharmaceuticals (MIST) Hits a Couple Milestones After FDA Meeting; Top Analyst Cheers TipRanks -7.07%
02:19PM	Juggling Risk And Reward In A Raucous Market Benzinga
Jul-23-20 07:00AM	Milestone Pharmaceuticals Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT PR Newswire +166.77%
07:00AM	Milestone Pharmaceuticals Announces $25 Million Private Placement PR Newswire
07:00AM	Milestone Pharmaceuticals Announces $25 Million Private Placement CNW Group
Jun-12-20 06:39AM	Milestone Pharmaceuticals' Shares March Higher, Can It Continue? Zacks
Jun-10-20 08:37AM	Milestone Pharmaceuticals (MIST) Looks Good: Stock Adds 6.5% in Session Zacks
Jun-05-20 02:46PM	Milestone Pharmaceuticals Inc. (MIST): Are Hedge Funds Right About This Stock? Insider Monkey
May-27-20 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference CNW Group
May-20-20 10:00AM	Backed by US and foreign investors, Canadian VC sets record at $7.263B for 2019 CNW Group +5.15%
08:33AM	Will Milestone Pharmaceuticals Continue to Surge Higher? Zacks
May-19-20 07:22AM	Top Ranked Momentum Stocks to Buy for May 19th Zacks
May-14-20 07:15AM	Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update PR Newswire
07:15AM	Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update CNW Group
Apr-20-20 10:38AM	Milestone Pharmaceuticals Enters Oversold Territory Zacks
Apr-02-20 01:23PM	LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day Zacks
Apr-01-20 10:15AM	3 Drugmakers Still Worth Betting on Amid Coronavirus Woes Zacks
Mar-25-20 10:34AM	Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More Zacks +14.71%
Mar-24-20 08:20AM	The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test Benzinga -87.86%
Mar-23-20 11:08PM	Milestone (MIST) Alert: Johnson Fistel Launches Investigation into Milestone Pharmaceuticals Inc.; Investors Suffering Losses Encouraged to Contact Firm PR Newswire +16.47%
04:05PM	Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment CNW Group
Mar-06-20 07:00AM	Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update PR Newswire +11.58%
07:00AM	Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update CNW Group
Feb-04-20 09:22AM	Here's Why We're Not Too Worried About Milestone Pharmaceuticals's (NASDAQ:MIST) Cash Burn Situation Simply Wall St.
Jan-15-20 07:00AM	Two Small Biotechs See Big Stock Purchases by Their Largest Holders Barrons.com
Dec-20-19 06:20PM	Should You Avoid Milestone Pharmaceuticals Inc. (MIST)? Insider Monkey
Nov-27-19 07:00AM	Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach CNW Group

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in Montreal, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience